Stay updated with breaking news from Immunovant Sciences. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Before U.S. markets open Thursday morning, 31 companies are scheduled to report quarterly earnings results. The following table is based on data from Briefing.com and includes a consensus forecast in dollars for quarterly earnings per share and EPS reported last year, and the consensus forecast for quarterly revenue in thousands of dollars. Companies marked with […]
Before U.S. markets open Friday morning, 40 companies are scheduled to report quarterly earnings results. No earnings reports are scheduled for release Friday afternoon. The following table is based on data from Briefing.com and includes a consensus forecast in dollars for quarterly earnings per share and EPS reported last year, and the consensus forecast for […]
The SEC case is the latest to highlight the risks investors run when they get involved with "blank check" companies.
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Immunovant, Inc. ("Immunovant" or "the Company") (NASDAQ: IMVT) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between October 2, 2019 and February 1, 2021, inclusive (the ''Class Period''), are encouraged to contact the firm before April 20, 2021. If you are a shareholder who suffered a loss, click her...
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Immunovant, Inc. f/k/a Health Sciences Acquisitions Corporation (NASDAQ: IMVT, HSACU, HSAC, HSACW) between October 2, 2019 and February 1, 2021, inclusive (the "Class Period"), of the important April 20, 2021 lead plaintiff deadline.